Entrada Therapeutics Director Trims Position by 2.8% in Form 4 Filing

Rhea-AI Filing Summary

Entrada Therapeutics (TRDA) – Form 4 insider transaction summary

Director and 10% owner Dr. Kush Parmar, through two affiliated venture funds, reported open-market sales totaling 125,000 common shares between 27 June and 1 July 2025. The sales were executed at prices ranging from $6.81 to $7.12 per share, generating roughly $0.9-1.2 million in proceeds (exact proceeds depend on final settlement).

• 5AM Ventures V, L.P. sold 92,891 shares across three trades and now owns 3,183,131 shares.
• 5AM Opportunities I, L.P. sold 32,109 shares and now owns 1,100,248 shares.
• The combined position after the transactions is approximately 4.28 million shares, meaning only about 2.8 % of their prior stake was divested.

No derivative securities were involved, and Dr. Parmar continues to disclaim beneficial ownership beyond his pecuniary interest. While insider selling often raises caution among investors, the modest percentage sold and the remaining large holding suggest routine portfolio rebalancing rather than a wholesale exit.

Positive

• Insider retains a substantial 4.28 million-share stake, demonstrating continued alignment with common shareholders and long-term interest.

Negative

• Director and 10% owner divested 125,000 shares (≈2.8% of position), which may be viewed as a mildly negative sentiment signal.

Insights

Securities Analyst

TL;DR: Small insider sale (≈2.8% of stake); signal is mildly negative but not materially impactful.

The three-day series of sales by funds managed by Director/10% owner Dr. Parmar reduces their aggregate position by 125k shares, leaving 4.28 million shares intact. Dollar proceeds are under $1.2 million, insignificant versus TRDA’s market cap. The share-price range near $7 aligns with recent trading averages, suggesting liquidity management rather than valuation call. Given continued >4 million-share ownership, strategic alignment remains. I view the filing as informational and neutral to slightly negative for sentiment but not financially material.

Corporate Governance Expert

TL;DR: Governance risk low; disclosure complies with Section 16, sale size immaterial.

Form 4 is properly filed within two business days, indicating sound compliance. Dr. Parmar’s role as both Director and 10% owner increases scrutiny, yet his funds’ divestiture is small relative to holdings and carries transparent footnotes clarifying indirect ownership and disclaimers. No derivative activity or 10b5-1 plan is cited. From a governance lens, the action neither improves nor degrades oversight quality; investors should simply note ongoing liquidity management.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PARMAR KUSH

(Last) (First) (Middle)

C/O 5AM VENTURE MANAGEMENT, LLC

4 EMBARCADERO CENTER, SUITE 3110

(Street)

SAN FRANCISCO CA 94111

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/27/2025		S		55,735	D	$6.91	3,220,287	I	By 5AM Ventures V, L.P.(1)
Common Stock	06/27/2025		S		19,265	D	$6.91	1,113,092	I	By 5AM Opportunities I, L.P.(2)
Common Stock	06/30/2025		S		18,578	D	$6.8127	3,201,709	I	By 5AM Ventures V, L.P.(1)
Common Stock	06/30/2025		S		6,422	D	$6.8127	1,106,670	I	By 5AM Opportunities I, L.P.(2)
Common Stock	07/01/2025		S		18,578	D	$7.1226	3,183,131	I	By 5AM Ventures V, L.P.(1)
Common Stock	07/01/2025		S		6,422	D	$7.1226	1,100,248	I	By 5AM Opportunities I, L.P.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Kush M. Parmar, M.D., Ph.D. is a managing member of 5AM Partners and may be deemed to share voting and investment power over the shares held by 5AM V. Dr. Parmar disclaims beneficial ownership of the shares held by 5AM V except to the extent of his pecuniary interest therein.

2. Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Kush M. Parmar, M.D., Ph.D. is a managing member of Opportunities GP and may be deemed to share voting and investment power over the shares held by Opportunities. Dr. Parmar disclaims beneficial ownership of the shares held by Opportunities except to the extent of his pecuniary interest therein.

	/s/ Kush Parmar	07/01/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Entrada Therapeutics (TRDA) shares did Dr. Kush Parmar sell?

The affiliated funds sold a total of 125,000 common shares between 27 June and 1 July 2025.

At what prices were the TRDA insider sales executed?

Trades were executed in a narrow band between $6.81 and $7.12 per share.

What is Dr. Parmar's remaining ownership in TRDA after the transactions?

The funds now hold approximately 4.28 million shares of Entrada Therapeutics common stock.

Does the Form 4 indicate any derivative transactions or option exercises?

No. The filing's Table II shows no derivative securities acquired or disposed of.

Is the insider sale considered material to TRDA investors?

Given that only about 2.8 % of the insider's prior stake was sold, the impact is viewed as not materially significant.